Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drugs in the class.

Q4 2024 Earnings Call Transcript May 29, 2025 Roivant Sciences Ltd. misses on earnings expectations. Reported EPS is $-0.22 ...

It isn't the first drug in the class to be cleared by the FDA for gMG – Argenx and UCB have FcRn blockers already on the market – but J&J thinks the broad label for Imaavy (nipocalimab ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY™ (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, for the ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY™ (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, for the treatment of ...

the firm acknowledges that the placebo-adjusted readout was mid-pack among FcRn inhibitors-better than nipocalimab but below argenx’s (ARGX) Vyvgart and UCB’s (UCBY) Rystiggo, the analyst ...

On Wednesday, 28 May 2025, Johnson & Johnson (NYSE:JNJ) presented at the Bernstein 41st Annual Strategic Decisions Conference. Chairman and CEO Joaquin Guato and CFO Joe Wall discussed the company ...

To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not ...